Weekly Recap | Pfizer -2.57%, consensus target above spot
Weekly Review·- Pfizer fell 2.57 % this week to close at 27.72 USD, underperforming the S & P 500 amid quiet trading and light volume. - Institutional ratings remain largely positive with a consensus buy rating and a target price of 28.875 USD, though opinions among analysts vary. - The company experienced quiet corporate developments while facing external market adjustments and upcoming macroeconomic data releases.Weekly Recap | Pfizer +1.75%, FDA clears XFG variant vaccine
Weekly Review·- Pfizer's stock rose 1.75 % this week to close at 28.45 dollars, outperforming the S & P 500 amid low trading volume. - Key catalysts included FDA approval for its XFG variant COVID-19 vaccine and a co-development agreement for a CD228V antibody-drug conjugate with Medicus Pharma. - Institutional sentiment remains split, with a consensus buy rating but a target price only 0.55 % above the current share price.Weekly Recap | Pfizer -0.39%, Lyme vaccine application accepted
Weekly Review·- Pfizer shares fell 0.39 % to close at 27.96 dollars this week, underperforming the S&P 500 index by 0.88 percentage points. - The European Medicines Agency accepted Pfizer’s Lyme disease vaccine application, which temporarily drove the stock to a high of 28.57 dollars on August 25. - A total of 28 institutions cover Pfizer with a consensus buy rating and an average target price of 28.60577 dollars, while upcoming catalysts include regulatory reviews and macroeconomic data releases.